Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ALK F1245C||Advanced Solid Tumor||sensitive||ALK Inhibitor||Brigatinib||Preclinical - Cell culture||Actionable||In a preclinical study, a transformed cell line expressing ALK F1245C was sensitive to Alunbrig (brigatinib) in culture, resulting in cell growth inhibition (PMID: 27049722).||27049722|
|ALK F1245C||neuroblastoma||resistant||ALK Inhibitor||Crizotinib||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, Xalkori (crizotinib) did not inhibit growth of neuroblastoma cells over expressing ALK F1245C in culture, and only delayed tumor growth in patient-derived xenograft models harboring ALK F1245C (PMID: 26554404).||26554404|
|ALK F1245C||neuroblastoma||sensitive||ALK Inhibitor||Lorlatinib||Preclinical - Pdx & cell culture||Actionable||In a preclinical study, Lorlatinib (PF-06463922) inhibited growth of neuroblastoma cells over expressing ALK F1245C in culture, and induced rapid and sustained complete tumor regression in patient-derived xenograft models harboring ALK F1245C (PMID: 26554404).||26554404|
|ALK F1245C||Advanced Solid Tumor||sensitive||ALK Inhibitor||Lorlatinib||Preclinical - Cell culture||Actionable||In a preclinical study, Lorlatinib (PF-06463922) inhibited foci formation more efficiently than Xalkori (crizotinib) in transformed cells over expressing ALK F1245C in culture (PMID: 26554404).||26554404|
|ALK F1245C||Advanced Solid Tumor||predicted - sensitive||ALK Inhibitor||TPX-0131||Preclinical - Biochemical||Actionable||In a preclinical study, TPX-0131 inhibited kinase activity of ALK F1245C in an in vitro assay (PMID: 34158340).||34158340|
|ALK F1245C||Advanced Solid Tumor||sensitive||ALK Inhibitor||Repotrectinib||Preclinical - Cell culture||Actionable||In a preclinical study, Repotrectinib (TPX-0005) decreased Alk phosphorylation and neurite outgrowth in cells expressing ALK F1245C in culture (PMID: 31852910).||31852910|
|ALK F1245C||neuroblastoma||sensitive||ALK Inhibitor||Ceritinib + Ribociclib||Preclinical - Cell line xenograft||Actionable||In a preclinical study, the combination of Zykadia (ceritinib) and Kisqali (ribociclib) inhibited proliferation in a neuroblastoma cell line harboring ALK F1245C in culture, and resulted in enhanced tumor growth inhibition compared to either Zykadia (ceritinib) or Kisqali (ribociclib) alone (P=0.04 and P<0.0001, respectively) and induced complete and sustained tumor regression in a patient-derived xenograft (PDX) model (PMID: 27986745).||27986745|